World Financial News Network
Dr. Joseph de Beauchamp of World Financial News Network started coverage and gives favorable analysis to IR BioSciences that helps with treatment of: acute radiation syndrome, acute lung injury/ acute respiratory distress syndrome and hair replacement related to loss due to traditional anti-cancer treatments.
Seattle, Washington. (PRWEB) October 17, 2004 -- WFNN's consistently outperforms established industry benchmark indicators. Based on in-depth research and analysis, their analysts recommend securities worldwide showing the highest probability for stock price appreciation. With constant vigil, WFNN looks for economic opportunities in the private and public company sectors.
Dr. Joseph de Beauchamp, WFNN's Chief Independent Analyst, said, "This Company helps with radiation, lung injury, hair loss, and bio-terrorism. Terrorism continues to increase. With pulmonary diseases continue growing, we see this company increasing the share price to $5.00 and earning five cents per share. The company plans to support grow on the large government grants and potential revenues with a product in high demand."
For brief information of this new, dynamic company, examine: http://wfnn.info displaying in the search engine section.
About WFNN: World Financial News Network provides a unique blend of data, timely information and today's technologies to assist with up-to-the-minute investment and economic values on markets and investments around the world.
About IR BioSciences: IR BioSciences Holdings specializes in the research and development of important life saving, health-enhancing therapeutic applications and therapies. The company's proprietary product, Homspera, derives from Substance P, a naturally occurring amino acid found within the human body. The company's vision to which it aspires is to be recognized as a leading developer of biotechnology products and applications for the 21st century. Based on initial studies and ongoing research, IR BioSciences Holdings and subsidiary ImmuneRegen BioSciences, they plan on developing applications using Homspera for the treatment of: acute radiation syndrome (ARS), acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) and hair replacement related to loss due to traditional anti-cancer treatments.
Michael Wilhelm, CEO
IR BioSciences Holdings, Inc.
4021 N. 75th Street, Suite 201
Scottsdale, Arizona 85251
408-922-3926
Mobile 602-684-1597
866-922-3926 Toll Free
mwilhelm@foresightcapitalcorporation.com
http://www.immuneregen.com
# # #
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
